USP <232>/<233> Elemental Impurities: What Pharmacy QA Should Ask Contract Labs

From “heavy metals” folklore to a modern control strategy

Older pharmaceutical conversations talked loosely about “heavy metals.” Modern compendial thinking centers on elemental impurities—specific elements with toxicological concern—organized through frameworks such as USP <232> Elemental Impurities—Limits and USP <233> Elemental Impurities—Procedures.

For compounding pharmacies and 503B facilities, elemental impurity questions most often appear when qualifying APIs, excipients, container concerns, or customer audit expectations. This guide helps non-chromatographers brief analytical contract labs intelligently.

What <232> and <233> do

• <232> — conceptual limits / control strategy context for elemental impurities
• <233> — procedures and analytical approaches commonly involving techniques such as ICP-MS / ICP-OES

Your quality system decides which components or preparations need testing versus documentation controls from suppliers. Not every compounded lot needs a full elemental panel—but when you do test, the lab brief must be specific.

When teams outsource elemental impurities work

Typical triggers:

1. New API supplier qualification
2. Excipient risk (mined minerals, colorants, certain botanicals)
3. Customer or quality-agreement requirements
4. Investigation after supplier change
5. 503B component risk assessments

Start with a risk assessment, not a shopping list of every element on earth.

Building an elemental impurities brief

Tell the lab:

• Material identity (API / excipient / preparation)
• Elements of interest (or ask them to propose a risk-based panel aligned to your rationale)
• Needed reporting limits / units
• Approximate concentration of material as tested
• Sample amount available
• Whether this is screening vs formal reportable method
• Matrix concerns (oils, high salt, organics)

ICP-MS sample prep is where timelines and costs hide—ask about digestion approach early.

Questions that reveal lab competence

1. Which technique will you use (ICP-MS vs ICP-OES) and why?
2. How do you handle spectral / matrix interferences for our material type?
3. What calibration and QC checks appear on the report?
4. Can you meet our target reporting limits?
5. Is the performing site on your ISO/IEC 17025 chemistry scope?

See also verifying accreditation scopes.

Reading results without false precision

Elemental data can look authoritative with many decimal places. Focus on:

• Whether results are above your control thresholds
• Uncertainty / validation context for the method
• Whether “< LOQ” is adequate for your risk decision
• Consistency across suppliers over time

One surprising spike deserves investigation before you rewrite the whole formulary.

How elemental testing differs from potency quotes

Potency assay	Elemental impurities
Strength of labeled API	Trace elements of toxicological concern
Often HPLC-centered	Often ICP-centered
Formula-specific method fit	Digestion + interference control critical

Do not assume your potency lab automatically owns elemental capability—confirm instrumentation and scope. Browse analytical CTLs on LabCompare Rx.

Quote comparison tips

• Panel size itemized (which elements)
• Sample prep / digestion fees visible
• Rush feasibility honest about prep bottlenecks
• Reporting limits stated
• Retest policy clear

Bottom line

Elemental impurities testing is a targeted risk tool. Define why you are testing, brief the matrix clearly, and choose labs with real ICP competence and pharmaceutical chemistry scope—not a generic “metals” menu.

Use LabCompare Rx to shortlist chemistry partners and keep every elemental bid on the same written panel definition.